DIXDC1 Antibody

What is DIXDC1 and what molecular functions does it perform?

DIXDC1, also known as Dixin or Ccd1, functions as a cytoplasmic signal transducer involved in the regulation of the Wnt signaling pathway . It serves as a positive effector of this pathway, specifically activating WNT3A signaling via DVL2 (Dishevelled 2). Additionally, DIXDC1 regulates JNK activation through interactions with AXIN1 and DVL2 . DIXDC1 is the mammalian homolog of Ccd1, which was originally identified in zebrafish as a positive regulator of Wnt-TCF/LEF signaling . The protein contains a DIX domain, making it only the third mammalian gene discovered to possess this Disheveled-Axin domain, which is critical for its function in developmental signaling pathways.

What expression patterns does DIXDC1 exhibit during neural development?

Immunostaining studies have demonstrated that DIXDC1 co-localizes with Nestin-positive radial glial cells in the embryonic cortex at E12 and E15 stages of development . These radial glial cells serve as neural progenitors that give rise to neurons during cortical development. Further analysis has shown that DIXDC1 also co-localizes with the neuronal marker β-III tubulin (Tuj1) in the E15 and E17 cortex . This expression pattern indicates that DIXDC1 is present in both neural progenitor cells (radial glia) and postmitotic neurons, suggesting its importance throughout different stages of neural development. This expression profile aligns with previous studies that have examined DIXDC1 patterns using in situ hybridization techniques.

What applications are DIXDC1 antibodies typically used for in research?

DIXDC1 antibodies are employed in various experimental applications depending on their specific characteristics. Common applications include Western Blot (WB), Immunohistochemistry (IHC), Immunoprecipitation (IP), and Enzyme-Linked Immunosorbent Assay (ELISA) . For instance, rabbit polyclonal DIXDC1 antibody (ab226210) is suitable for immunoprecipitation and western blotting with reactivity to human samples . Similarly, DIXDC1 antibody (13816-1-AP) has been validated for WB, IHC, and ELISA applications with demonstrated reactivity to both human and mouse samples . These antibodies have been used to study DIXDC1's role in neural progenitor proliferation, neuronal migration, and its interactions with key developmental signaling pathways such as the Wnt signaling cascade.

What are the common species reactivity profiles for DIXDC1 antibodies?

DIXDC1 antibodies exhibit varying reactivity profiles across species. Many commercially available antibodies have been tested and validated for human and mouse reactivity . For example, rabbit polyclonal DIXDC1 antibody (ab226210) primarily reacts with human samples , while mouse Ccd1/DIXDC1 antibody (AF5599) has been specifically designed to detect mouse DIXDC1 . The DIXDC1 antibody (13816-1-AP) from Proteintech demonstrates reactivity with both human and mouse samples and has been cited for reactivity with rat samples as well . When selecting a DIXDC1 antibody, researchers should carefully review the documented species reactivity to ensure compatibility with their experimental model system.

How does DIXDC1 interact with DISC1 to regulate neural development?

DIXDC1 forms a functional complex with DISC1 (Disrupted in Schizophrenia-1) that regulates both neural progenitor proliferation and neuronal migration through distinct molecular mechanisms . Biochemical analyses using E14 brain tissue have confirmed that Dixdc1 and DISC1 co-immunoprecipitate during embryonic development when neural progenitor proliferation is highly prevalent . Domain mapping experiments revealed that Dixdc1 binds most strongly to the C-terminus of DISC1 and weakly to its middle region, while DISC1 strongly binds to the N-terminal Dixdc1 region located between the calpain homology and coiled-coil domains .

What are the optimal conditions for immunodetection of DIXDC1 in different tissue types?

For detecting DIXDC1 in brain tissue, western blotting protocols have been optimized using specific conditions. When using mouse Ccd1/DIXDC1 antibody (AF5599), lysates of mouse brain tissue should be probed with 1 μg/mL of the antibody followed by HRP-conjugated secondary antibody . This approach has successfully detected specific DIXDC1 bands at approximately 59 and 45 kDa under reducing conditions using appropriate immunoblot buffers .

For immunohistochemistry applications in human tissues, DIXDC1 antibody (13816-1-AP) has been validated for detection in multiple tissue types including heart, kidney, testis, skin, lung, and ovary tissue . Optimal antigen retrieval involves using TE buffer at pH 9.0, although citrate buffer at pH 6.0 can serve as an alternative . The recommended dilution range for IHC applications is 1:50-1:500, though the optimal concentration should be determined for each specific tissue type and experimental system . For embryonic mouse tissues, Ccd1/DIXDC1 has been successfully detected in immersion-fixed frozen sections of mouse embryo (13 d.p.c.) using 15 μg/mL of antibody incubated overnight at 4°C, followed by visualization with HRP-DAB staining and hematoxylin counterstaining .

How can DIXDC1 knockdown approaches be used to study neuronal development?

DIXDC1 knockdown experiments using shRNA have provided valuable insights into its role in neural progenitor proliferation and neuronal migration . When designing such experiments, researchers should test multiple shRNA constructs for their knockdown efficiency. Previous studies have successfully reduced both exogenous and endogenous Dixdc1 expression using targeted shRNA approaches . For in vivo studies, in utero electroporation has been utilized to introduce Dixdc1 shRNA constructs along with GFP-encoding plasmids into neural progenitor cells of developing mouse embryos at E13, with analysis performed at E16 .

This approach revealed that Dixdc1 knockdown results in a significant redistribution of cells within the developing cortex, with reduced presence in both the ventricular/subventricular zones and the cortical plate, accompanied by accumulation in the intermediate zone . To specifically assess effects on neural progenitor proliferation, BrdU pulse-labeling experiments can be performed (injecting BrdU into pregnant dams 24 hours prior to brain analysis) . When implementing DIXDC1 knockdown experiments, appropriate controls should include scrambled shRNA constructs to account for non-specific effects of the electroporation and shRNA expression.

What methods can be used to study DIXDC1 phosphorylation and its functional consequences?

DIXDC1 phosphorylation, particularly by cyclin-dependent kinase 5 (Cdk5), is crucial for its role in neuronal migration through facilitating interactions with DISC1 and Ndel1 . To study this phosphorylation, researchers can employ phospho-specific antibodies that recognize the phosphorylated residues of DIXDC1. Additionally, phosphorylation status can be assessed indirectly through mobility shift assays in western blots, where phosphorylated forms of DIXDC1 may display altered migration patterns compared to non-phosphorylated forms.

Functional studies of DIXDC1 phosphorylation can be conducted using phosphomimetic and phospho-dead mutants. By replacing specific phosphorylation sites with amino acids that either mimic (e.g., aspartate or glutamate) or prevent (e.g., alanine) phosphorylation, researchers can assess the impact of DIXDC1 phosphorylation on protein-protein interactions and downstream cellular processes. Co-immunoprecipitation experiments with DISC1 and Ndel1 can then be performed to determine how phosphorylation affects complex formation. Furthermore, these mutants can be expressed in neuronal cultures or in utero electroporation models to evaluate their effects on neuronal migration and morphology.

How can DIXDC1 antibodies be employed to investigate its role in Wnt signaling pathways?

DIXDC1 functions as a positive effector of the Wnt signaling pathway, activating WNT3A signaling via DVL2 . To investigate this role, researchers can use DIXDC1 antibodies in conjunction with antibodies against other Wnt pathway components in co-immunoprecipitation experiments to isolate and characterize protein complexes. Western blotting with DIXDC1 antibodies can be performed following Wnt pathway stimulation or inhibition to assess how pathway modulation affects DIXDC1 expression or post-translational modifications.

For cellular localization studies, immunofluorescence with DIXDC1 antibodies can reveal changes in subcellular distribution in response to Wnt signaling activation. Chromatin immunoprecipitation (ChIP) assays using antibodies against DIXDC1 and Wnt pathway transcription factors can help identify target genes co-regulated by these factors. Additionally, proximity ligation assays (PLA) with DIXDC1 antibodies paired with antibodies against Wnt pathway components can provide direct evidence of protein-protein interactions in situ with subcellular resolution. These approaches collectively enable detailed investigation of DIXDC1's role in canonical and non-canonical Wnt signaling pathways.

What are the optimal storage conditions for maintaining DIXDC1 antibody activity?

DIXDC1 antibodies require specific storage conditions to maintain their activity and specificity. Most DIXDC1 antibodies should be stored at -20°C, where they remain stable for at least one year after shipment . The storage buffer typically consists of PBS with 0.02% sodium azide and 50% glycerol at pH 7.3, which helps preserve antibody integrity . For antibodies supplied in small volumes (e.g., 20μl), manufacturers may include 0.1% BSA to prevent protein loss through adsorption to container surfaces .

How can researchers validate the specificity of DIXDC1 antibodies for their experimental systems?

Validating DIXDC1 antibody specificity is crucial for generating reliable experimental data. A multi-faceted validation approach is recommended. First, researchers should perform western blot analysis using positive control samples known to express DIXDC1, such as mouse brain tissue or specific cell lines . The presence of specific bands at the expected molecular weight (approximately 70-75 kDa or 59 and 45 kDa, depending on the isoform) provides initial validation.

For more rigorous validation, researchers should include negative controls such as DIXDC1 knockout tissues/cells or samples treated with DIXDC1-targeting siRNA/shRNA. The absence or significant reduction of signal in these samples confirms antibody specificity. Peptide competition assays, where the antibody is pre-incubated with its immunizing peptide before application, can further demonstrate binding specificity - signal abolishment indicates specific antibody-antigen interaction. For immunohistochemistry applications, researchers should verify that the staining pattern matches known DIXDC1 expression patterns, such as localization to neopallial cortex and midbrain in embryonic tissues .

What troubleshooting approaches are recommended for inconsistent DIXDC1 antibody signals?

When encountering inconsistent signals with DIXDC1 antibodies, several troubleshooting strategies can be employed. For weak or absent signals in western blotting, researchers should optimize protein loading amounts, consider using more sensitive detection methods, verify transfer efficiency, and potentially adjust antibody concentration. The recommended dilution ranges (e.g., 1:500-1:3000 for WB, 1:50-1:500 for IHC) provide starting points, but titration is often necessary for optimal results.

For high background or non-specific signals, increasing blocking agent concentration, using alternative blockers, optimizing antibody dilution, and incorporating additional washing steps can improve signal-to-noise ratio. Sample preparation methods may also affect antibody performance - for IHC applications, optimizing antigen retrieval methods is crucial, with DIXDC1 antibodies often requiring TE buffer at pH 9.0 or citrate buffer at pH 6.0 . If inconsistencies persist across multiple experiments, comparison with alternative DIXDC1 antibody clones can help determine if the issue is antibody-specific or related to the experimental system.

How can DIXDC1 antibodies be used to study neurodevelopmental disorders?

DIXDC1's functional interaction with DISC1, a gene implicated in psychiatric disorders, positions it as a valuable target for studying neurodevelopmental conditions . Researchers can employ DIXDC1 antibodies to investigate alterations in DIXDC1 expression, localization, or post-translational modifications in animal models of neurodevelopmental disorders or in human postmortem brain tissues. Immunohistochemistry using optimized DIXDC1 antibodies can reveal changes in expression patterns across different brain regions and developmental stages.

Co-immunoprecipitation experiments utilizing DIXDC1 antibodies can identify disruptions in protein-protein interactions, particularly with DISC1 and components of the Wnt signaling pathway, which might contribute to abnormal neurodevelopment . For functional studies, researchers can combine DIXDC1 antibody-based detection methods with in utero electroporation or genetic models to assess how DIXDC1 dysregulation affects neural progenitor proliferation and neuronal migration - processes frequently disrupted in neurodevelopmental disorders . Additionally, phospho-specific DIXDC1 antibodies could reveal alterations in Cdk5-mediated phosphorylation, which is crucial for proper neuronal migration and potentially implicated in developmental brain disorders.

What approaches can be used to study DIXDC1-protein interactions using antibody-based methods?

Multiple antibody-based approaches can effectively investigate DIXDC1's interactions with partner proteins. Co-immunoprecipitation represents a fundamental technique where DIXDC1 antibodies immobilized on a substrate (such as protein A/G beads) can pull down DIXDC1 along with its interacting partners from cell or tissue lysates . This method has successfully demonstrated DIXDC1's interaction with DISC1 in embryonic brain tissue . Subsequent western blotting with antibodies against suspected binding partners can confirm these interactions.

For studying interactions with specific domains, researchers can combine co-immunoprecipitation with expression of tagged DIXDC1 fragments. This approach has revealed that DISC1 strongly binds to DIXDC1's N-terminal region between the calpain homology and coiled-coil domains . Proximity ligation assays (PLA) offer an alternative for visualizing protein-protein interactions in situ with subcellular resolution. This technique uses DIXDC1 antibodies in conjunction with antibodies against potential interacting proteins, followed by oligonucleotide-conjugated secondary antibodies that generate fluorescent signals when the target proteins are in close proximity.

How can DIXDC1 antibodies contribute to understanding neural progenitor proliferation mechanisms?

DIXDC1 antibodies provide valuable tools for investigating the molecular mechanisms underlying neural progenitor proliferation. Immunofluorescence staining of embryonic brain sections using DIXDC1 antibodies, combined with markers for proliferating cells (such as Ki67 or phospho-histone H3) and neural progenitor markers (such as Nestin or Sox2), can reveal DIXDC1's distribution within actively dividing neural progenitor populations . This approach has demonstrated DIXDC1's co-localization with Nestin-positive radial glial cells in the embryonic cortex .

For functional studies, researchers can use DIXDC1 antibodies to assess how manipulations of the Wnt-GSK3β/β-catenin pathway affect DIXDC1 expression, localization, or post-translational modifications. Since DIXDC1 and DISC1 cooperatively regulate neural progenitor proliferation through this pathway , western blotting with DIXDC1 antibodies following pathway modulation can provide insights into regulatory mechanisms. Furthermore, chromatin immunoprecipitation (ChIP) experiments using DIXDC1 antibodies can identify potential genomic regions where DIXDC1 might influence transcription of genes involved in progenitor proliferation, potentially in conjunction with β-catenin or other transcriptional regulators.

What emerging techniques might enhance DIXDC1 antibody applications in neural development research?

Emerging technologies offer promising avenues for expanding DIXDC1 antibody applications in neural development research. Single-cell protein analysis techniques, such as mass cytometry (CyTOF) using metal-conjugated DIXDC1 antibodies, could enable high-dimensional profiling of DIXDC1 expression across heterogeneous neural cell populations. This approach would provide unprecedented insights into how DIXDC1 levels vary among distinct neural progenitor subtypes and differentiating neurons.

Super-resolution microscopy techniques (STORM, PALM, STED) combined with highly specific DIXDC1 antibodies could reveal nanoscale details of DIXDC1's subcellular localization and co-localization with interaction partners that are not visible with conventional microscopy. For studying dynamics in living systems, genetically encoded intrabodies derived from DIXDC1 antibodies could enable real-time tracking of DIXDC1 localization and interactions during neural development without cell fixation. Additionally, spatially-resolved transcriptomics combined with DIXDC1 immunostaining could correlate DIXDC1 protein expression with transcriptional profiles across developing brain regions, providing integrated insights into its regulatory networks.

How might phospho-specific DIXDC1 antibodies advance understanding of its regulation?

Development of phospho-specific antibodies targeting key DIXDC1 phosphorylation sites would significantly advance our understanding of its regulation and function. Given that Cdk5-mediated phosphorylation of DIXDC1 is crucial for its role in neuronal migration through facilitating interactions with DISC1 and Ndel1 , phospho-specific antibodies would enable detailed spatial and temporal mapping of this regulatory modification across brain development. These antibodies could reveal when and where DIXDC1 phosphorylation occurs in relation to neurodevelopmental processes.

Such antibodies would also facilitate investigations into additional kinases that might phosphorylate DIXDC1 under different conditions or at different residues, potentially uncovering novel regulatory mechanisms. Furthermore, quantitative assays using phospho-specific DIXDC1 antibodies could assess how various neurodevelopmental stimuli or pathological conditions alter DIXDC1 phosphorylation status. In disease models, these antibodies could determine whether phosphorylation abnormalities contribute to developmental disorders associated with neuronal positioning defects, potentially identifying new therapeutic targets for conditions involving aberrant neural circuit formation.